ArticleGeriatrics & gerontology international2026
Comparison of Metabolic Dysfunction-Associated Steatotic Liver Disease Between Individuals With Werner Syndrome and Those With Insulin-Resistant Type 2 Diabetes: Hepatic Steatosis and Fibrosis Indices.
Article in Geriatrics & gerontology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
Abstract
aimThis study compared metabolic dysfunction-associated steatotic liver disease (MASLD) in individuals with Werner syndrome (WS) and individuals with insulin-resistant type 2 diabetes (T2D). It also examined the association with imaging findings of MASLD in individuals with WS, clarified the characteristics of MASLD that accompany WS, and identified useful indices for its diagnosis in addition to imaging.
methodsThree hepatic steatosis and two hepatic fibrosis indices in 48 individuals enrolled in the Japanese Werner Syndrome Registry were compared with those in 101 Japanese individuals with insulin-resistant T2D from another clinical study. In individuals with WS, the liver/spleen ratio (L/S ratio) was calculated from computed tomography (CT) images, and its associations with each index were examined. Statistical analyses were performed using the Welch test and pairwise comparisons.
resultsIndividuals with WS had lower hepatic steatosis and fibrosis index values than those with insulin-resistant T2D. The mean L/S ratio calculated from CT images was 1.05 ± 0.24 in individuals with WS. The L/S ratio, which is one of the indicators for diagnosing MASLD, was < 0.9 in 5 of 20 cases (25%). Among the various indices in individuals with WS, only the hepatic steatosis index (HSI) was correlated with the L/S ratio (r = -0.863, p = 0.0003).
conclusionsThe prevalence of MASLD is lower in individuals with WS than in those with insulin-resistant T2D. The HSI was associated with the L/S ratio in individuals with WS, suggesting that HSI may reflect hepatic steatosis-related changes in this population. Further studies in larger cohorts are needed to validate these findings.
trial registrationThe study was registered at the UMIN Clinical Trial Registry (https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034058) on November 3, 2017 (ID: UMIN000029812).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.